Skip to content

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Irradiation for Chinese Breast Cancer Patients :Comparative Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05609058
Enrollment
300
Registered
2022-11-08
Start date
2019-01-01
Completion date
2023-11-01
Last updated
2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, radiotherapy

Brief summary

Radiotherapy after breast conserving therapy plays an important role in early stage breast cancer patients. It not only results in a reduction in local and regional recurrence but also decrease the death rate effectively. For adjuvant radiotherapy, supine positioning is the most common approach and has multiple advantages. Due to deformability and softness of the breast, during simulation and treatment in supine position, the breast stretches over the chest wall, especially in patients with large and pendulous glands. Thus the organs at risk (OARs) received dose increased. The radiotherapeutic toxicity are unavoidable. Some present studies show that the prone positioning of patients can improve dose homogeneity and reduce the dose distribution in OARs in patients with large and pendulous glands. Chinese women have relatively small breasts, the advantages of those have not been established. Therefore, investigators compared the parameters between supine and prone positions for whole breast irradiation after conserving surgery.

Detailed description

Objective To investigate the difference of target volumes and dosimetric parameters between supine and prone positions for whole breast irradiation after conserving surgery. Methods Breast cancer patients with T1-2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine and Prone scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist. The tumor bed (TB) was determined based on surgical clips. The Clinical target volume (CTV)consisted of the whole breast. The planning target volume (PTV) was CTV plus 0.5cm. The boost of PTV (PTVboost) was TB plus 0.5cm. Dosimetric parameters of target volumes and OARs were compared between supine and prone position.

Interventions

DEVICEdedicated treatment board with no degree

the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Breast cancer patients with T1-T2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine and Prone scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Breast cancer patients with T1-T2N0M0 stage who underwent radiation therapy after conserving surgery 2. exhibited normal arm movement aſter surgery 3. had no chronic lung diseases 4. Written informed consent forms

Exclusion criteria

1. Breast cancer patients with radical surgery 2. could not exhibit normal arm movement after surgery 3. had chronic lung diseases 4. refused informed consent forms

Design outcomes

Primary

MeasureTime frameDescription
dose distribution of GTV1 yearthe difference of GTV (Gross tumor target) between two plans
dose distribution of CTV1 yearthe difference of CTV (clinical target volume) between two plans
dose distribution of PTV1 yearthe difference of PTV (planing target volume) between two plans
dose distribution of heart1 yearthe difference of heart dose distribution between two plans
dose distribution of ipsilateral lung1 yearthe difference of ipsilateral lung dose distribution between two plans
dose distribution of bilateral breasts1 yearthe difference of bilateral breasts dose distribution between two plans

Countries

China

Contacts

Primary ContactNing Li
liningnci@126.com13521952929

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026